Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis

被引:60
|
作者
Pearce, Fiona A. [1 ,2 ]
Craven, Anthea [3 ]
Merkel, Peter A. [4 ,5 ]
Luqmani, Raashid A. [3 ]
Watts, Richard A. [6 ,7 ]
机构
[1] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham, England
[2] Nottingham Univ Hosp NHS Trust, Dept Rheumatol, Nottingham, England
[3] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[4] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[6] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England
[7] Ipswich Hosp NHS Trust, Dept Rheumatol, Ipswich, Suffolk, England
关键词
ANCA-vasculitis; epidemiology; PR3-ANCA; MPO-ANCA; ANCA-ASSOCIATED VASCULITIS; SYSTEMIC VASCULITIS; CLASSIFICATION; GRANULOMATOSIS; EPIDEMIOLOGY; POLYANGIITIS; ALLELES;
D O I
10.1093/rheumatology/kex293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. There are few data on clinical profiles of ANCA-associated vasculitis (AAV) in different ethnic populations. The aim of this study was to examine the differences in the ANCA type and clinical features of AAV between populations using the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS) dataset. Methods. The DCVAS is an international, multicentre, observational study recruiting in 133 sites. Eight ethnic categories were analysed: Northern European, Caucasian American, Southern European, Middle Eastern/Turkish, Chinese, Japanese, Indian subcontinent and other. ANCA type was categorized as myeloperoxidase (MPO), PR3 and ANCA negative. Organ system involvement was recorded using a standard dataset. Differences were analysed by chi-squared tests using a Bonferroni correction and logistic regression (adjusting for age and sex). Northern European was the reference population. Results. Data from 1217 patients with AAV were available and the 967 (79.5%) patients recruited by rheumatology departments were analysed to reduce confounding by recruitment specialty. There were differences in ANCA type between ethnic categories (P < 0.001): MPO-ANCA was more common than PR3-ANCA in Japanese, Chinese and Southern Europeans; PR3-ANCA was more common in the other groups. Compared with Northern Europeans, Japanese had a nearly 60-fold increased chance of having MPO-ANCA (vs PR3-ANCA) [odds ratio (OR) 59.2 (95% CI 8.0, 440.7), P < 0.001] and Chinese had a nearly 7-times increased chance [OR 6.8 (95% CI 2.6, 17.8), P < 0.001]. Ophthalmologic and otorhinolaryngologic involvement were less common in Japanese and Chinese populations than Northern Europeans; otherwise, there were few differences in organ involvement between ethnic groups. Conclusion. This study confirms the previously observed differential occurrence of MPO-AAV and PR3-AAV between different ethnic groups.
引用
收藏
页码:1962 / 1969
页数:8
相关论文
共 50 条
  • [1] Autoantibodies in anti-neutrophil cytoplasm antibody-associated vasculitis
    Salama, Alan D.
    Rees, Andrew J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (06) : 1105 - 1107
  • [2] Rituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis
    Jones, Rachel B.
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 243 - 249
  • [3] Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis
    Sayer, Matthew
    Chapman, Gavin B.
    Thomas, Matthew
    Dhaun, Neeraj
    CURRENT RHEUMATOLOGY REPORTS, 2024, 26 (01) : 12 - 23
  • [4] Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis
    Matthew Sayer
    Gavin B. Chapman
    Matthew Thomas
    Neeraj Dhaun
    Current Rheumatology Reports, 2024, 26 : 12 - 23
  • [5] Strawberry carina as a presentation of anti-neutrophil cytoplasm antibody-associated vasculitis
    Chapman, Gavin B.
    Leitch, Andrew E.
    Lahiri, Rashmi
    Reid, Peter
    Dhaun, Neeraj
    RHEUMATOLOGY, 2022, 61 (03) : E59 - E61
  • [6] Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis
    Guerry, Mary-Jane C. J.
    Brogan, Paul
    Bruce, Ian N.
    D'Cruz, David P.
    Harper, Lorraine
    Luqmani, Raashid
    Pusey, Charles D.
    Salama, Alan D.
    Scott, David G. I.
    Savage, Caroline O. S.
    Watts, Richard A.
    Jayne, David R. W.
    RHEUMATOLOGY, 2012, 51 (04) : 634 - 643
  • [7] Anti-neutrophil cytoplasm antibody associated vasculitis
    Hewins, P
    Savage, C
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (03): : 277 - 282
  • [8] Plasma exchange as an adjunctive therapy in anti-neutrophil cytoplasm antibody-associated vasculitis
    Gulati, Kavita
    Pusey, Charles D.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (04) : 417 - 430
  • [9] Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis
    Walsh, Michael
    Tonelli, Marcello
    Jayne, David
    Manns, Braden
    JOURNAL OF NEPHROLOGY, 2007, 20 (02) : 119 - 129
  • [10] EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
    Hellmich, Bernhard
    Flossmann, Oliver
    Gross, Wolfgang L.
    Bacon, Paul
    Cohen-Tervaert, Jan Willem
    Guillevin, Loic
    Jayne, David
    Mahr, Alfred
    Merkel, Peter A.
    Raspe, Heiner
    Scott, David G. I.
    Witter, James
    Yazici, Hasan
    Luqmani, Raashid A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (05) : 605 - 617